The Mitral Valve Disease Market is growing due to rising heart valve disorders and increasing use of minimally invasive treatments

The global mitral valve disease market size was evaluated at $3.7 billion in 2023 and is slated to hit $7.7 billion by the end of 2032 with a CAGR of nearly 8% between 2024 and 2032.

Mitral valve disease is a condition affecting the mitral valve, one of four valves in the human heart that control blood flow between the left atrium and left ventricle. When this valve does not open or close properly, blood flow becomes inefficient, placing extra strain on the heart and potentially leading to serious complications, including heart failure. The two most common forms of this condition are mitral valve regurgitation, in which the valve leaks and allows blood to flow backward, and mitral valve stenosis, in which the valve becomes narrowed and restricts blood flow. Treatment options range from medications that manage symptoms to surgical procedures that either repair or replace the damaged valve. Repairs are generally preferred over replacements because they preserve the patient's own tissue, but in severe cases, replacement with mechanical or biological valves becomes necessary. More recently, catheter-based procedures that do not require open-heart surgery have become increasingly popular because they carry a lower risk and allow faster patient recovery. Mitral valve disease affects people across all age groups but is more common among older adults, particularly those with a history of rheumatic fever, high blood pressure, or other cardiovascular conditions.

The mitral valve disease market is growing due to the increasing global burden of cardiovascular disease, aging populations, and ongoing innovation in transcatheter and minimally invasive valve therapies.

Browse the full “Mitral Valve Disease Market By Treatment Type (Mitral Valve Repair, Mitral Valve Therapeutics, Mitral Valve Replacement, and Cardiac Resynchronization Therapy), By Indication (Mitral Valve Prolapse, Mitral Regurgitation, and Mitral Stenosis), By End-User (Ambulatory Surgical Centers, Hospitals, and Clinics), and By Region - Global and Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, and Forecasts 2024 - 2032” Report at https://www.zionmarketresearch.com/report/mitral-valve-disease-market

Market Growth Factors

Several important factors are accelerating development and investment in the mitral valve disease market.

• Aging global population: As people live longer, heart valves naturally weaken, increasing the number of patients worldwide who need treatment.
• Minimally invasive technology advances: New catheter-based treatments allow doctors to fix valve problems without major surgery, helping older and high-risk patients.
• Improved diagnostic capabilities: Advanced imaging and testing tools help doctors detect mitral valve disease earlier, leading to timely treatment and better outcomes.

Restraints

• High treatment costs: Mitral valve procedures, especially advanced and minimally invasive ones, are expensive and often unaffordable for many patients worldwide.
• Skilled specialist shortage: These treatments require highly trained heart specialists, and limited availability in many regions makes access to care more difficult.

Mitral Valve Disease Market: Report Scope

 Market Segmentation

The mitral valve disease market can be segmented by disease type, treatment type, end user, and region.

Based on disease type, the mitral valve disease industry is divided into mitral valve regurgitation and mitral valve stenosis. Mitral valve regurgitation leads the market as it is the more prevalent form of the condition globally and accounts for the majority of surgical and catheter-based interventions performed each year.

Based on treatment type, the mitral valve disease market is classified into surgical valve repair, surgical valve replacement, transcatheter mitral valve repair, and transcatheter mitral valve replacement. Transcatheter mitral valve repair is growing fastest due to its minimally invasive nature and suitability for elderly and high-risk patient populations.

Based on end user, the market is segmented into hospitals, cardiac specialty centers, and ambulatory surgical centers. Hospitals hold the largest market share because most mitral valve procedures require advanced imaging equipment, cardiac intensive care units, and surgical teams that are typically available only in hospital settings.

North America leads the mitral valve disease market, driven by advanced healthcare infrastructure, high cardiovascular disease awareness, and strong access to specialized cardiac care. The United States plays a major role due to the high prevalence of heart valve disorders and a well-established network of hospitals and cardiac centers. Early diagnosis through advanced imaging technologies and routine health screenings supports timely treatment, increasing procedure volumes. The region also benefits from the rapid adoption of minimally invasive and transcatheter mitral valve repair technologies, improving patient outcomes and recovery times. Strong presence of leading medical device companies and continuous innovation further boost market growth. In addition, favorable reimbursement policies and high healthcare spending enable wider access to advanced treatments, helping North America maintain its leading position in the mitral valve disease market.

Key Market Players

Leading companies operating in the global mitral valve disease market include:

• Artivion Inc.
• Boston Scientific Corporation
• Corcym UK Limited
• 4C Medical Technologies
• Edwards Lifesciences Corporation
• Bayer AG
• Abbott Laboratories
• Valcare Medical
• Medtronic plc
• LivaNova PLC
• Zydus Lifesciences Limited
• Pfizer Inc.
• JenaValve Technology Inc.
• ShockWave Medical Inc.
• Novartis AG
• CryoLife Inc.
• Braile Biomedica.

 Recent Developments

• In January 2026, Edwards Lifesciences received FDA approval for its SAPIEN M3 transcatheter mitral valve replacement system, designed for high-risk patients and delivered using a minimally invasive transseptal approach.
• In September 2025, Abbott Laboratories completed the first commercial U.S. implantation of its Tendyne TMVR system, marking a key milestone in the adoption of minimally invasive mitral valve therapies.

The global mitral valve disease market is segmented as follows:

By Treatment Type

• Mitral Valve Repair
• Mitral Valve Therapeutics
• Mitral Valve Replacement
• Cardiac Resynchronization Therapy

By Indication

• Mitral Valve Prolapse
• Mitral Regurgitation
• Mitral Stenosis

By End-User

• Ambulatory Surgical Centers
• Hospitals
• Clinics

​By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa

About Us:

Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

Contact Us:

Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
Email: sales@zionmarketresearch.com
Website: https://www.zionmarketresearch.co